474 related articles for article (PubMed ID: 30039978)
21. Efficacy and safety of edoxaban compared with warfarin in patients with atrial fibrillation and heart failure: insights from ENGAGE AF-TIMI 48.
Magnani G; Giugliano RP; Ruff CT; Murphy SA; Nordio F; Metra M; Moccetti T; Mitrovic V; Shi M; Mercuri M; Antman EM; Braunwald E
Eur J Heart Fail; 2016 Sep; 18(9):1153-61. PubMed ID: 27349698
[TBL] [Abstract][Full Text] [Related]
22. Anticoagulation Control in Warfarin-Treated Patients Undergoing Cardioversion of Atrial Fibrillation (from the Edoxaban Versus Enoxaparin-Warfarin in Patients Undergoing Cardioversion of Atrial Fibrillation Trial).
Lip GYH; Al-Saady N; Jin J; Sun M; Melino M; Winters SM; Zamoryakhin D; Goette A
Am J Cardiol; 2017 Sep; 120(5):792-796. PubMed ID: 28709650
[TBL] [Abstract][Full Text] [Related]
23. Transition of patients from blinded study drug to open-label anticoagulation: the ENGAGE AF-TIMI 48 trial.
Ruff CT; Giugliano RP; Braunwald E; Mercuri M; Curt V; Betcher J; Grip L; Cange AL; Crompton AE; Murphy SA; Deenadayalu N; Antman EM
J Am Coll Cardiol; 2014 Aug; 64(6):576-84. PubMed ID: 25104527
[TBL] [Abstract][Full Text] [Related]
24. Impact of Renal Function on Outcomes With Edoxaban in the ENGAGE AF-TIMI 48 Trial.
Bohula EA; Giugliano RP; Ruff CT; Kuder JF; Murphy SA; Antman EM; Braunwald E
Circulation; 2016 Jul; 134(1):24-36. PubMed ID: 27358434
[TBL] [Abstract][Full Text] [Related]
25. Cardiovascular- and Bleeding-Related Hospitalization Rates With Edoxaban Versus Warfarin in Patients With Atrial Fibrillation Based on Results of the ENGAGE AF-TIMI 48 Trial.
Vilain K; Li H; Kwong WJ; Antman EM; Ruff CT; Braunwald E; Cohen DJ; Giugliano RP; Magnuson EA;
Circ Cardiovasc Qual Outcomes; 2020 Nov; 13(11):e006511. PubMed ID: 33148013
[TBL] [Abstract][Full Text] [Related]
26. Genetics and the clinical response to warfarin and edoxaban: findings from the randomised, double-blind ENGAGE AF-TIMI 48 trial.
Mega JL; Walker JR; Ruff CT; Vandell AG; Nordio F; Deenadayalu N; Murphy SA; Lee J; Mercuri MF; Giugliano RP; Antman EM; Braunwald E; Sabatine MS
Lancet; 2015 Jun; 385(9984):2280-7. PubMed ID: 25769357
[TBL] [Abstract][Full Text] [Related]
27. Edoxaban for the management of elderly Japanese patients with atrial fibrillation ineligible for standard oral anticoagulant therapies: Rationale and design of the ELDERCARE-AF study.
Okumura K; Lip GYH; Akao M; Tanizawa K; Fukuzawa M; Abe K; Akishita M; Yamashita T
Am Heart J; 2017 Dec; 194():99-106. PubMed ID: 29223441
[TBL] [Abstract][Full Text] [Related]
28. Valvular Heart Disease Patients on Edoxaban or Warfarin in the ENGAGE AF-TIMI 48 Trial.
De Caterina R; Renda G; Carnicelli AP; Nordio F; Trevisan M; Mercuri MF; Ruff CT; Antman EM; Braunwald E; Giugliano RP
J Am Coll Cardiol; 2017 Mar; 69(11):1372-1382. PubMed ID: 28302288
[TBL] [Abstract][Full Text] [Related]
29. Intracranial hemorrhage in patients with atrial fibrillation receiving anticoagulation with warfarin or edoxaban: An in-depth analysis from the ENGAGE AF-TIMI 48 randomized trial.
Nelson SE; Giugliano RP; Antman EM; Park JG; Norden AD; Rost NS; Silverman S; Singhal AB; Lanz HJ; Braunwald E; Ruff CT;
J Clin Neurosci; 2021 Apr; 86():294-300. PubMed ID: 33446422
[TBL] [Abstract][Full Text] [Related]
30. Edoxaban Versus Warfarin in Patients With Atrial Fibrillation and History of Liver Disease.
Qamar A; Antman EM; Ruff CT; Nordio F; Murphy SA; Grip LT; Greenberger NJ; Yin OQP; Choi Y; Lanz HJ; Mercuri MF; Braunwald E; Giugliano RP
J Am Coll Cardiol; 2019 Jul; 74(2):179-189. PubMed ID: 31296289
[TBL] [Abstract][Full Text] [Related]
31. Efficacy and Safety of Edoxaban in Patients With Active Malignancy and Atrial Fibrillation: Analysis of the ENGAGE AF - TIMI 48 Trial.
Fanola CL; Ruff CT; Murphy SA; Jin J; Duggal A; Babilonia NA; Sritara P; Mercuri MF; Kamphuisen PW; Antman EM; Braunwald E; Giugliano RP
J Am Heart Assoc; 2018 Aug; 7(16):e008987. PubMed ID: 30369307
[TBL] [Abstract][Full Text] [Related]
32. Clinical outcomes in patients with atrial fibrillation and frailty: insights from the ENGAGE AF-TIMI 48 trial.
Wilkinson C; Wu J; Searle SD; Todd O; Hall M; Kunadian V; Clegg A; Rockwood K; Gale CP
BMC Med; 2020 Dec; 18(1):401. PubMed ID: 33357217
[TBL] [Abstract][Full Text] [Related]
33. Edoxaban vs. warfarin in vitamin K antagonist experienced and naive patients with atrial fibrillation†.
O'Donoghue ML; Ruff CT; Giugliano RP; Murphy SA; Grip LT; Mercuri MF; Rutman H; Shi M; Kania G; Cermak O; Braunwald E; Antman EM
Eur Heart J; 2015 Jun; 36(23):1470-7. PubMed ID: 25687352
[TBL] [Abstract][Full Text] [Related]
34. Edoxaban versus warfarin in patients with atrial fibrillation in relation to the risk of stroke: A secondary analysis of the ENGAGE AF-TIMI 48 study.
de Groot JR; Ruff CT; Murphy SA; Hamershock RA; Vehmeijer JT; Oude Ophuis AJM; Grip L; Lanz H; Mercuri MF; Antman EM; Giugliano RP
Am Heart J; 2021 May; 235():132-139. PubMed ID: 33493453
[TBL] [Abstract][Full Text] [Related]
35. Ischaemic and bleeding risk in atrial fibrillation with and without peripheral artery disease and efficacy and safety of full- and half-dose edoxaban vs. warfarin: insights from ENGAGE AF-TIMI 48.
Bonaca MP; Antman EM; Cunningham JW; Wiviott SD; Murphy SA; Halperin JL; Weitz JI; Grosso MA; Lanz HJ; Braunwald E; Giugliano RP; Ruff CT
Eur Heart J Cardiovasc Pharmacother; 2022 Sep; 8(7):695-706. PubMed ID: 34962979
[TBL] [Abstract][Full Text] [Related]
36. Edoxaban Versus Warfarin in Latin American Patients With Atrial Fibrillation: The ENGAGE AF-TIMI 48 Trial.
Corbalán R; Nicolau JC; López-Sendon J; Garcia-Castillo A; Botero R; Sotomora G; Horna M; Ruff CT; Hamershock RA; Grip LT; Antman EM; Braunwald E; Giugliano RP
J Am Coll Cardiol; 2018 Sep; 72(13):1466-1475. PubMed ID: 30236308
[TBL] [Abstract][Full Text] [Related]
37. Edoxaban: A direct oral anticoagulant.
Poulakos M; Walker JN; Baig U; David T
Am J Health Syst Pharm; 2017 Feb; 74(3):117-129. PubMed ID: 28122753
[TBL] [Abstract][Full Text] [Related]
38. Edoxaban versus Warfarin in Patients with Atrial Fibrillation at the Extremes of Body Weight: An Analysis from the ENGAGE AF-TIMI 48 Trial.
Boriani G; Ruff CT; Kuder JF; Shi M; Lanz HJ; Antman EM; Braunwald E; Giugliano RP
Thromb Haemost; 2021 Feb; 121(2):140-149. PubMed ID: 32920808
[TBL] [Abstract][Full Text] [Related]
39. Randomised, parallel-group, multicentre, multinational phase 2 study comparing edoxaban, an oral factor Xa inhibitor, with warfarin for stroke prevention in patients with atrial fibrillation.
Weitz JI; Connolly SJ; Patel I; Salazar D; Rohatagi S; Mendell J; Kastrissios H; Jin J; Kunitada S
Thromb Haemost; 2010 Sep; 104(3):633-41. PubMed ID: 20694273
[TBL] [Abstract][Full Text] [Related]
40. Edoxaban and implantable cardiac device interventions: insights from the ENGAGE AF-TIMI 48 trial.
Steffel J; Ruff CT; Braunwald E; Hamershock RA; Murphy SA; Nieminen M; Lanz HJ; Mercuri MF; Peterson N; Antman EM; Giugliano RP
Europace; 2019 Feb; 21(2):306-312. PubMed ID: 30462220
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]